Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.
Blacksmith Medicines has raised $3.3M in total funding. The most recent round was Grant. The last funding was announced in February 2024.
Blacksmith Medicines's investors include Eli Lilly, Evotec, Alexandria Venture Investments, National Institute of Allergy and Infectious Diseases, U.S. Department of Health & Human Services.
Blacksmith Medicines is headquartered in San Diego, United States.
Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.
Blacksmith Medicines is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Blacksmith Medicines — Funding & Investors." VCBacked, February 21, 2024, https://www.vcbacked.co/company/blacksmith-medicines. Accessed September 12, 2026.
VCBacked. (2024). Blacksmith Medicines — Funding & Investors. Retrieved September 12, 2026, from https://www.vcbacked.co/company/blacksmith-medicines
{{cite web |title=Blacksmith Medicines — Funding & Investors |url=https://www.vcbacked.co/company/blacksmith-medicines |website=VCBacked |access-date=September 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated